Allogene Therapeutics (ALLO) Stock Price, News & Analysis

Company Overview

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Key Stats

• Today's Range: $1.32 to $1.46
• 50-Day Range: $1.37 to $2.83
• 52-Week Range: $1.30 to $4.25
• Volume: 3.59 million shs
• Average Volume: 3.17 million shs
• Market Capitalization: $312.86 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.29
• Consensus Rating: Moderate Buy

Allogene Therapeutics Stock Analysis - MarketRank™

Allogene Therapeutics scored higher than 45% of companies evaluated by MarketBeat, and ranked 554th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Allogene Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 9 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Allogene Therapeutics has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Allogene Therapeutics are expected to decrease in the coming year, from ($1.28) to ($1.35) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Allogene Therapeutics is -0.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Allogene Therapeutics is -0.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Allogene Therapeutics has a P/B Ratio of 0.47. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

27.24% of the float of Allogene Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Allogene Therapeutics has a short interest ratio ("days to cover") of 7.1.

Change versus previous month

Short interest in Allogene Therapeutics has recently decreased by 2.79%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Allogene Therapeutics does not currently pay a dividend.

Dividend Growth

Allogene Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

27.24% of the float of Allogene Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Allogene Therapeutics has a short interest ratio ("days to cover") of 7.1.

Change versus previous month

Short interest in Allogene Therapeutics has recently decreased by 2.79%, indicating that investor sentiment is improving.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 2 news articles for Allogene Therapeutics this week, compared to 4 articles on an average week.

Search Interest

Only 5 people have searched for ALLO on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.

MarketBeat Follows

8 people have added Allogene Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 4.2 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Allogene Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $194,461.00 in company stock.

Percentage Held by Insiders

24.30% of the stock of Allogene Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

83.63% of the stock of Allogene Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ALLO Stock Analysis - Frequently Asked Questions

How have ALLO shares performed this year?

Allogene Therapeutics' stock was trading at $2.13 on January 1st, 2025. Since then, ALLO stock has decreased by 32.4% and is now trading at $1.44.
View the best growth stocks for 2025 here.

How were Allogene Therapeutics' earnings last quarter?

Allogene Therapeutics, Inc. (NASDAQ:ALLO) posted its quarterly earnings results on Thursday, March, 13th. The company reported ($0.28) earnings per share for the quarter, beating the consensus estimate of ($0.34) by $0.06.

When did Allogene Therapeutics IPO?

Allogene Therapeutics (ALLO) raised $272 million in an initial public offering (IPO) on Thursday, October 11th 2018. The company issued 16,000,000 shares at $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan, Cowen and Jefferies acted as the underwriters for the IPO.

How do I buy shares of Allogene Therapeutics?

Shares of ALLO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Allogene Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Allogene Therapeutics investors own include Waste Connections (WCN), American Water Works (AWK), Humana (HUM), Voyager Therapeutics (VYGR), The RMR Group (RMR), AUO (AUOTY) and DiamondRock Hospitality (DRH).

Company Calendar

• Last Earnings: 3/13/2025
• Today: 4/04/2025
• Next Earnings (Estimated): 5/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ALLO
• CIK: 1737287
• Web: www.allogene.com
• Phone: (650) 457-2700
• Fax: N/A
• Employees: 310
• Year Founded: 2018

Price Target and Rating

• Average Stock Price Target: $9.29
• High Stock Price Target: $14.00
• Low Stock Price Target: $4.60
• Potential Upside/Downside: +545.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.90
• Research Coverage: 10 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.33)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-327,270,000.00
• Net Margins: N/A
• Pretax Margin: -659,137.19%
• Return on Equity: -52.13%
• Return on Assets: -41.29%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.35
• Quick Ratio: 9.35

Sales & Book Value

• Annual Sales: $22,000.00
• Price / Sales: 14,220.98
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.04 per share
• Price / Book: 0.47

Miscellaneous

• Outstanding Shares: 217,265,000
• Free Float: 158,722,000
• Market Cap: $312.86 million
• Optionable: Optionable
• Beta: 0.99